Dupixent Side Effects
Generic name: dupilumab
Note: This document provides detailed information about Dupixent Side Effects associated with dupilumab. Some dosage forms listed on this page may not apply specifically to the brand name Dupixent.
Applies to dupilumab: subcutaneous solution.
Serious side effects of Dupixent
Along with its needed effects, dupilumab (the active ingredient contained in Dupixent) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking dupilumab:
More common side effects
- blistering, peeling, redness, or swelling of the palms, hands, or bottoms of the feet
- body aches or pain
- burning or dry eyes
- chills
- cough
- difficulty in breathing
- ear congestion
- excessive tearing
- fever
- headache
- loss of voice
- muscle aches
- numbness, pain, tingling, or unusual sensations in the palms of the hands or bottoms of the feet
- pain, redness, irritation, itching, or swelling of the eye, eyelid, or inner lining of the eyelid
- sneezing
- sore throat
- stuffy or runny nose
- unusual tiredness or weakness
Less common side effects
- black, tarry stools
- blistering, crusting, or reddening of the skin
- bone, joint, or muscle pain
- burning, tingling, or numbness in the hands and feet
- burning or stinging of the skin
- chest pain
- difficulty in moving
- lump or growth on the skin
- muscle cramps or stiffness
- painful cold sores or blisters on the lips, nose, eyes, or genitals
- painful or difficult urination
- scaly patches on the skin
- skin rash
- sores or white patches on the lips, mouth, or throat
- swollen glands
- swollen joints
- unusual bleeding or bruising
Rare side effects
- feeling of discomfort
- hives, itching
- lightheadedness, dizziness, fainting
- pain in the groin or legs, especially the calves
- pain or swelling in the joints
- severe, sudden headache
- slurred speech
- sudden loss of coordination
- sudden, severe weakness or numbness in the arm or leg
- swelling of the hands, face, or mouth
- trouble breathing
- trouble swallowing
- vision changes
Incidence not known
- large, hive-like swelling on face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
Other side effects of Dupixent
Some side effects of dupilumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common side effects
- bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
Less common side effects
- burning feeling in the chest or stomach
- diarrhea
- indigestion
- mouth or throat pain
- stomach upset
- tenderness in the stomach area
- toothache
- trouble sleeping
For healthcare professionals
Applies to dupilumab: subcutaneous solution.
General adverse events
The most common adverse reactions were injection site reactions (which included erythema, edema, pruritus, pain, and swelling), conjunctivitis, allergic conjunctivitis, arthralgia, oral herpes, and eosinophilia.
The most common adverse reactions reported in patients with atopic dermatitis included injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia.
The most common adverse reactions reported in patients with asthma included injection site reactions, oropharyngeal pain, and eosinophilia.
The most common adverse reactions reported in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP) included injection site reactions, eosinophilia, insomnia, toothache, gastritis, arthralgia, and conjunctivitis.
The most common adverse reactions reported in patients with eosinophilic esophagitis included injection site reactions, upper respiratory tract infections, arthralgia, and herpes viral infections.
The most common adverse reactions reported in patients with prurigo nodularis included nasopharyngitis, conjunctivitis, herpes infection, dizziness, myalgia, and diarrhea.[Ref]
Cardiovascular
- Uncommon (0.1% to 1%): Cardiovascular thromboembolic events (cardiovascular deaths, nonfatal myocardial infarctions, nonfatal strokes)
- Frequency not reported: Vasculitis
Vasculitis consistent with eosinophilic granulomatosis with polyangiitis was reported in adult patients in the asthma development program and adult patients with comorbid asthma in the CRSwNP development program.
Dermatologic
- Frequency not reported: Skin papilloma
- Postmarketing reports: Angioedema, facial skin reactions
Facial skin reactions (including erythema, rash, scaling, edema, papules, pruritus, burning, and pain) have been reported during postmarketing experience.
Gastrointestinal
- Common (1% to 10%): Oral herpes, gastritis, toothache, diarrhea
Hematologic
- Common (1% to 10%): Eosinophilia
Hypersensitivity
- Rare (0.01% to 0.1%): Anaphylactic reaction, serum sickness reaction, serum sickness-like reaction
- Frequency not reported: Hypersensitivity reactions
Hypersensitivity reactions (including anaphylaxis, serum sickness/serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme) have been reported.
Immunologic
- Common (1% to 10%): Antidrug antibodies (ADA), persistent ADA responses, neutralizing antibodies
- Frequency not reported: Eosinophilic granulomatosis with polyangiitis
Local
- Very common (10% or more): Injection site reaction (up to 38%), injection site erythema (up to 14.6%)
- Common (1% to 10%): Injection site edema, injection site pruritus
- Frequency not reported: Injection site bruising
Injection site reaction included injection site reaction, injection site erythema, injection site edema, injection site pruritus, injection site pain, injection site inflammation, injection site bruising, and injection site swelling.
Musculoskeletal
- Common (1% to 10%): Arthralgia, myalgia
Myalgia included musculoskeletal pain and musculoskeletal chest pain.
Nervous system
- Common (1% to 10%): Dizziness
Dizziness included postural dizziness, vertigo, and positional vertigo.
Ocular
- Very common (10% or more): Conjunctivitis (up to 21%)
- Common (1% to 10%): Blepharitis, keratitis, eye pruritus, dry eye, allergic conjunctivitis, bacterial conjunctivitis
- Frequency not reported: Ophthalmic herpes zoster
- Postmarketing reports: Ulcerative keratitis
Conjunctivitis included conjunctivitis, allergic conjunctivitis, bacterial conjunctivitis, viral conjunctivitis, giant papillary conjunctivitis, eye irritation, and eye inflammation.
Keratitis included keratitis, ulcerative keratitis, allergic keratitis, atopic keratoconjunctivitis, and ophthalmic herpes simplex.
Other
- Very common (10% or more): Infections (up to 32%)
- Common (1% to 10%): Other herpes simplex virus infection, herpes infection, serious infections
- Frequency not reported: Hand-foot-and-mouth disease, helminth infections, eczema herpeticum, herpes zoster
Other herpes simplex virus infection included herpes simplex, genital herpes, herpes simplex otitis externa, and herpes virus infection, and excluded eczema herpeticum.
Herpes infection included herpes viral infections, oral herpes, herpes simplex, genital herpes simplex, herpes zoster, and ophthalmic herpes zoster.
Helminth infections (including enterobiasis and ascariasis) have been reported.
Psychiatric
- Common (1% to 10%): Insomnia
Respiratory
- Very common (10% or more): Upper respiratory tract infections (up to 18%)
- Common (1% to 10%): Oropharyngeal pain, nasopharyngitis
- Frequency not reported: Eosinophilic pneumonia
Upper respiratory tract infections included COVID-19, sinusitis, and upper respiratory tract infection.
Nasopharyngitis included pharyngitis.
Eosinophilic pneumonia was reported in adult patients in the asthma development program.
References
1. (2024) "Product Information. Dupixent Pre-filled Syringe (dupilumab)." sanofi-aventis, SUPPL-59
2. (2024) "Product Information. Dupixent (dupilumab)." Sanofi-Aventis Australia Pty Ltd, dupi-ccdsv26-piv14-1
3. (2024) "Product Information. Dupixent (dupilumab)." Sanofi Genzyme
Frequently asked questions
- What are the most common skin conditions? (with photos)
- Why do Dupixent injections hurt so much?
- How fast does Dupixent work?
- Why does Dupixent cause eye problems?
- Is Dupixent an immunosuppressant?
- Does Dupixent cause weight gain?
- How long can Dupixent stay out of the fridge?
- Can you drink alcohol on Dupixent?
- How does Dupixent work and what is its mechanism of action?
More about Dupixent (dupilumab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (486)
- Drug images
- Dosage information
- Patient tips
- During pregnancy
- Support group
- FDA approval history
- Drug class: interleukin inhibitors
- Breastfeeding
Patient resources
Professional resources
Related treatment guides
Further information
Dupixent side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.